No profile data available.
Cardio Diagnostics Holdings, Inc. (CDIO) is a healthcare company in the DNA testing equipment industry, based in Chicago, United States, with about 15 full-time employees.
It reported revenue of $34,890 for fiscal year 2024, up 104.5% from fiscal year 2023, and net income of -$8.38 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $2,855, down 56.6% from a year before. Its market capitalization was $5.53 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease.
Cardio Diagnostics reported $34,890 in revenue for fiscal year 2024, up 104.5% from $17,065 in fiscal year 2023. In Q3 2025 revenue was $2,855.
$5.53 million as of October 9, 2026.
Listed companies of a similar size in the same industry (DNA testing equipment) include PAVmed Inc. (PAVM), Aspira Women's Health Inc. (AWHL), Co-Diagnostics, Inc. (CODX), Epigenomics AG N (EPGNF).